6th Annual Cell Engager Summit

Prioritizing Back Translation from Bedside to Bench and Novel Targets
With a whopping 7 approvals in the last two years, the field is alive with positive clinical read outs and the drive to get more life changing cell engager therapeutics to patients in indications of huge unmet need.

The timely 6th Cell Engager Therapeutics Summit is back once again to meet the needs of the community, focused on reaching new indications by expanding the target space and focusing our content to novel targets as well as continuing the push to focus on the translational challenges of developing cell engager therapies for solid and liquid tumors.

Join 100+ of your colleagues from JNJ, Astellas, Amgen, CDR-Life, Regeneron, Immunocore, Crossbow Therapeutics and AstraZeneca in discovery and translational sciences, learn from clinical case studies to back translate, improve engineering by tuning affinity via adapting engager format and mitigating cytokine release syndrome. This is your one stop shop for all of the must have content dedicated to all engagers such as T-cell engagers, BiTe's, gamma delta engagers and NK engagers.

As we look to prioritize the next generation intracellular targets, how you go about validating, discovering, and creating the next therapies to target them, the power of cell engager technology is clear. Overcome your key challenges in developing cell engagers across three days of highly focused content - don't miss out!

URLs:
Website: https://go.evvnt.com/2241394-0?pid=10018
Tickets: https://go.evvnt.com/2241394-2?pid=10018
Brochure: https://go.evvnt.com/2241394-3?pid=10018
LinkedIn: https://go.evvnt.com/2241394-4?pid=10018

Prices:
Conference + Pre-Conference Day - Drug Developer Rate: USD 4297.00,
Conference Only - Drug Developer Rate: USD 2999.00,
Conference + Pre-Conference Day - Academic Rate: USD 3697.00,
Conference Only - Academic Rate: USD 2599.00,
Conference + Pre-Conference Day - Solution Provider Rate: USD 5197.00,
Conference Only - Solution Provider Rate: USD 3699.00

Speakers: Angus Sinclair, Senior Vice President - Immuno-Oncology, IGM Biosciences, Annelise Vuidepot, Chief Technology Officer - Head of Pipeline and Platform Research site Head, Immunocore Ltd, Anthony Steinz, Associate Director, City of Hope, Cedric Dos Santos, Director AML/MDS/MM, Translational Medicine, Genentech, Dmitri Wiederschain, Chief Scientific Officer, Crossbow Therapeutics, Elizabeth Pham, Senior Principal Scientist, Amgen Inc., Flavio Lima, Bianchi Research Analyst, Hanson Wade, Hongtao Lu, Co-Founder and Chief Scientific Officer, Elpiscience, Huan Yang, Associate Principal Scientist, Merck and Co, Jessica Kirshner, Executive Director, Regeneron Pharmaceuticals Inc, Martin Felices, Associate Professor of Medicine and Director of Translational Therapy Lab, University of Minnesota, Nadia Hassounah, Principal Scientist, Novartis AG, Patricia Giblin, Senior Vice President - Biology, Revitope Oncology, Rajkumar Ganesan, Executive Director, Amgen Inc., Robert McGray, Assistant Professor - Oncology and Immunotherapy, Roswell Park, Saso Cemerski, Executive Director and Head of Immune Engagers, AstraZeneca, Sean Arlauckas, Director, B Cell Platform, Be Biopharma, Siddhartha Roychoudhury, Immuno Oncology Development Asset Leader, Astellas Innovation Management LLC, Swethajit Biswas, Chief Medical Officer, CDR-Life Inc, Volker Schellenberger, President and Chief Executive Officer, Amunix Pharmaceuticals Inc.